Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice

Nature Medicine

Volumn 22, Issue 11, 2016, Pages 1351-1357

  Das, Rituparna ^a   Strowig, Till ^a,d   Verma, Rakesh ^a   Koduru, Srinivas ^a   Hafemann, Anja ^a   Hopf, Stephanie ^a   Kocoglu, Mehmet H ^a   Borsotti, Chiara ^b   Zhang, Lin ^a   Branagan, Andrew ^a   Eynon, Elizabeth ^a   Manz, Markus G ^b   Flavell, Richard A ^a   Dhodapkar, Madhav V ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c YALE CANCER CENTER   (United States)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER GROWTH; CD3+ T LYMPHOCYTE; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GAMMOPATHY; HETEROZYGOSITY LOSS; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PHENOTYPE; PLASMA CELL; PLASMA CELL DYSCRASIA; PLASMA CELL LEUKEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CYTOLOGY; HUMAN; PRECANCER; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW; CELL PROLIFERATION; CELLULAR MICROENVIRONMENT; HUMANS; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PLASMA CELLS; PRECANCEROUS CONDITIONS; TUMOR MICROENVIRONMENT;

EID: 84990978868     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4202     Document Type: Article

References (34)

1. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046-1060 (2011).
2. Schüler, J., Ewerth, D., Waldschmidt, J., Wäsch, R. & Engelhardt, M. Preclinical models of multiple myeloma: a critical appraisal. Expert Opin. Biol. Ther. 13 (Suppl. 1), S111-S123 (2013).
3. Yaccoby, S., Barlogie, B. & Epstein, J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908-2913 (1998).
4. Calimeri, T. et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25, 707-711 (2011).
5. Rongvaux, A. et al. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu. Rev. Immunol. 31, 635-674 (2013).
6. Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364-372 (2014).
7. Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385 (2015).
8. Kishimoto, T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
9. Kishimoto, T., Akira, S. & Taga, T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 258, 593-597 (1992).
10. Tassone, P. et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106, 713-716 (2005).
11. Matsui, W. et al. Characterization of clonogenic multiple myeloma cells. Blood 103, 2332-2336 (2004).
12. Hosen, N. et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 26, 2135-2141 (2012).
13. + plasma cells enrich for human tumorigenic myeloma cells. Leukemia 26, 2530-2537 (2012).
14. Kukreja, A. et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J. Exp. Med. 203, 1859-1865 (2006).
15. Klco, J.M. et al. Functional heterogeneity of genetically defned subclones in acute myeloid leukemia. Cancer Cell 25, 379-392 (2014).
16. Goyama, S., Wunderlich, M. & Mulloy, J.C. Xenograft models for normal and malignant stem cells. Blood 125, 2630-2640 (2015).
17. Zhao, S. et al. Serial exome analysis of disease progression in premalignant gammopathies. Leukemia 28, 1548-1552 (2014).
18. Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fuorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108, 1724-1732 (2006).
19. Nair, S. et al. Clonal immunoglobulin against lysolipids in the origin of myeloma. N. Engl. J. Med. 374, 555-561 (2016).
20. Koduru, S. et al. Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. Blood 119, 2302-2309 (2012).
21. Dhodapkar, M.V. & Dhodapkar, K.M. Immune modulation in hematologic malignancies. Semin. Oncol. 42, 617-625 (2015).
22. Melchor, L. et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 28, 1705-1715 (2014).
23. Ghobrial, I.M. Myeloma as a model for the process of metastasis: implications for therapy. Blood 120, 20-30 (2012).
24. Walker, B.A. et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28, 384-390 (2014).
25. López-Corral, L. et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin. Cancer Res. 17, 1692-1700 (2011).
26. Dhodapkar, M.V. et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123, 78-85 (2014).
27. Dhodapkar, M.V. et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197, 1667-1676 (2003).
28. Dhodapkar, M.V., Krasovsky, J., Osman, K. & Geller, M.D. Vigorous premalignancy-specifc effector T cell response in the bone marrow of patients with monoclonal gammopathy. J. Exp. Med. 198, 1753-1757 (2003).
29. Spisek, R. et al. Frequent and specifc immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J. Exp. Med. 204, 831-840 (2007).
30. Dhodapkar, M.V. et al. Prospective analysis of antigen-specifc immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 126, 2475-2478 (2015).
31. Lawson, M.A. et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat. Commun. 6, 8983 (2015).
32. Sehgal, K. et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 125, 4042-4051 (2015).
33. Zhao, S. et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl. Acad. Sci. USA 110, 2916-2921 (2013).
34. + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768-772 (2011).